Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 3/20 | 0.39 |
| ▸ | CCR2 | P41597 | 3/20 | 0.39 |
| ▸ | F10 | P00742 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29349011 | 0.98 | HSD17B10 (0.42) | PARP1HSD17B10CCR1CCR2F10 | |
| SCHEMBL5880744 | 0.94 | HSD17B10 (0.46) | PARP1HSD17B10CCR1CCR2F10 | |
| SCHEMBL31642786 | 0.94 | HSD17B10 (0.46) | PARP1HSD17B10CCR1CCR2F10 | |
| SCHEMBL85665 | 0.83 | ALDH1A1 (0.44) | PARP1HSD17B10F10ALDH1A1MEN1 | |
| SCHEMBL12848677 | 0.82 | HSD17B10 (0.44) | PARP1HSD17B10CCR1CCR2F10 | |
| SCHEMBL2651529 | 0.81 | PARP1 (0.50) | PARP1HSD17B10ALDH1A1MEN1TSHR | |
| SCHEMBL76589 | 0.81 | ALDH1A1 (0.45) | PARP1HSD17B10F10ALDH1A1MEN1 | |
| SCHEMBL22816936 | 0.80 | HSD17B10 (0.42) | HSD17B10F10ALDH1A1MEN1TSHR | |
| SCHEMBL16190037 | 0.80 | PARP1 (0.42) | PARP1HSD17B10F10ALDH1A1KDM4E | |
| SCHEMBL8305775 | 0.80 | HSD17B10 (0.45) | PARP1HSD17B10CCR1CCR2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100340559-C | Nitrogen containing heterobicycles as factor XA inhibitors | DU PONT PHARM CO (US) | 2007-10-03 | — | — | CN | disclosed |
| US-6858616-B2 | Nitrogen containing heterobicycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1140941-B1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030069237-A1 | Nitrogen containing heterobicycles as factor Xa inhibitors | FEVIG JOHN M (US) | 2003-04-10 | — | — | US | disclosed |
| US-6413980-B1 | INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASE ENZYMES; ANTICOAGULANTS; THROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-02 | — | — | US | disclosed |
| EP-1140941-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039131-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069237-A1 | Nitrogen containing heterobicycles as factor Xa inhibitors | F12, F11, F10 | PARP1 1637/4885HSD17B10 2599/4885CCR1 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.